{"id":11968,"date":"2023-11-07T22:22:00","date_gmt":"2023-11-07T14:22:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11968"},"modified":"2024-11-10T22:30:06","modified_gmt":"2024-11-10T14:30:06","slug":"gsk-acquires-global-rights-to-janssens-hepatitis-b-antiviral-jnj-3989-in-1-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11968","title":{"rendered":"GSK Acquires Global Rights to Janssen&#8217;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal"},"content":{"rendered":"\n<p>GlaxoSmithKline (GSK; <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson &amp; Johnson&#8217;s (J&amp;J; <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.<\/p>\n\n\n\n<p><strong>GSK&#8217;s Development Plans for JNJ-3989<\/strong><br>GSK plans to progress the molecule into Phase II clinical trials next year in combination with its antisense oligonucleotide bepirovirsen. Bepirovirsen is currently in Phase III of development as a potential functional cure for non-cirrhotic patients with chronic hepatitis B (CHB) who are on nucleoside or nucleotide analogue (NA) therapy. This strategic move by GSK aims to enhance its hepatitis B treatment portfolio and provide new treatment options for patients. <\/p>\n\n\n\n<p><strong>Financial Terms and Ongoing Trials<\/strong><br>Under the terms of the deal, GSK will provide Janssen and Arrowhead with up to USD 1 billion in upfront and potential milestone payments. GSK will also assume all remaining financial obligations owed to Arrowhead under the original license agreement with Janssen. Furthermore, Janssen will complete all ongoing trials involving JNJ-3989, while Arrowhead remains eligible to receive tiered royalties from the commercialization of the drug.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[29,278,184,150,1996,149,914,858,89],"class_list":["post-11968","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-combination-therapy","tag-glaxosmithkline","tag-gsk","tag-jj","tag-janssen","tag-johnson-johnson","tag-nyse-gsk","tag-nyse-jnj","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Acquires Global Rights to Janssen&#039;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson &amp; Johnson&#039;s (J&amp;J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11968\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Acquires Global Rights to Janssen&#039;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11968\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-07T14:22:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-10T14:30:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Acquires Global Rights to Janssen&#8217;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal\",\"datePublished\":\"2023-11-07T14:22:00+00:00\",\"dateModified\":\"2024-11-10T14:30:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968\"},\"wordCount\":215,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Combination therapy\",\"GlaxoSmithKline\",\"GSK\",\"J&amp;J\",\"Janssen\",\"Johnson &amp; Johnson\",\"NYSE: GSK\",\"NYSE: JNJ\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11968#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11968\",\"name\":\"GSK Acquires Global Rights to Janssen's Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-07T14:22:00+00:00\",\"dateModified\":\"2024-11-10T14:30:06+00:00\",\"description\":\"GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson & Johnson's (J&J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11968\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Acquires Global Rights to Janssen&#8217;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Acquires Global Rights to Janssen's Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson & Johnson's (J&J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11968","og_locale":"en_US","og_type":"article","og_title":"GSK Acquires Global Rights to Janssen's Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11968","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-07T14:22:00+00:00","article_modified_time":"2024-11-10T14:30:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11968#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11968"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Acquires Global Rights to Janssen&#8217;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal","datePublished":"2023-11-07T14:22:00+00:00","dateModified":"2024-11-10T14:30:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11968"},"wordCount":215,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Combination therapy","GlaxoSmithKline","GSK","J&amp;J","Janssen","Johnson &amp; Johnson","NYSE: GSK","NYSE: JNJ","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11968#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11968","url":"https:\/\/flcube.com\/?p=11968","name":"GSK Acquires Global Rights to Janssen's Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-07T14:22:00+00:00","dateModified":"2024-11-10T14:30:06+00:00","description":"GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson & Johnson's (J&J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11968"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Acquires Global Rights to Janssen&#8217;s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11968"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11968\/revisions"}],"predecessor-version":[{"id":11973,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11968\/revisions\/11973"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}